Keyphrases
Atrial Fibrillation
100%
Warfarin
100%
New Alternatives
100%
Alternative Anticoagulants
100%
Dabigatran
42%
Stroke Prevention
28%
Intracranial Bleeding
28%
Rivaroxaban
28%
Preventing Stroke
28%
Apixaban
28%
Increased Safety
14%
Increasing Prevalence
14%
Safety Profile
14%
All-cause Mortality
14%
Drug Interactions
14%
Drug Choice
14%
Ischemic Stroke
14%
Improved Efficacy
14%
New Agents
14%
Randomized Trial
14%
Major Bleeding
14%
New Anticoagulants
14%
Anticoagulant Agents
14%
Once-daily Dosing
14%
Non-inferiority
14%
Regular Monitoring
14%
Aristotle
14%
Stroke Prophylaxis
14%
User-friendliness
14%
RE-LY
14%
Food Interaction
14%
Net Clinical Benefit
14%
Effective Stroke
14%
Individual Stability
14%
Stroke Prevention in Atrial Fibrillation
14%
Individual Preferences
14%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
100%
Warfarin
100%
Atrial Fibrillation
100%
Cerebrovascular Accident
85%
Dabigatran
42%
Brain Hemorrhage
28%
Rivaroxaban
28%
Apixaban
28%
Bleeding
14%
Prevalence
14%
Drug Interaction
14%
Brain Ischemia
14%
All Cause Mortality
14%
Drug Choice
14%